HPV genotypea | CIN3 | Adenocarcinoma in situ | Squamous cell carcinoma | Adenocarcinoma | Invasive cancers (Squamous cell and adenocarcinoma) |
---|---|---|---|---|---|
N = 702 | N = 33 | N = 24 | N = 9 | N = 33 | |
n, % (95 CI) | n, %, (95 CIb) | n, %, (95 CIb) | n, %, (95 CIb) | n, %, (95 CIb) | |
HPV 16 and/or 18 | 427, 60.8 (57.1–64.5) | 24, 72.7 (54.5–86.7) | 16, 66.7 (44.7–84.4) | 8, 88.9 (51.8–99.7) | 24, 72.7 (54.5–86.7) |
HVP 16 positive | 398, 56.7 (52.9–60.4) | 18, 54.5 (36.4–71.9) | 14, 58.3 (36.6–77.9) | 5, 55.6 (21.2–86.3) | 19, 57.6 (39.2–74.5) |
HPV 18 positive | 36, 5.1 (3.6–7.0) | 7, 21.2 (9.0–38.9) | 3, 12.5 (2.7–32.4) | 4, 44.4 (13.7–78.8) | 7, 21.2 (9.0–38.9) |
Any type in nonavalent vaccinec | 626, 89.2 (86.6–91.4) | 29, 87.9 (71.8–96.6) | 23, 95.8 (78.9–99.9) | 9, 100.0 (66.4–100.0) | 32, 97.0 (84.2–99.9) |
Any other IARC oncogenic type not in nonavalent vaccinec | 56, 8.0 (6.1–10.2) | 1, 3.0 (0.1–15.8) | 1, 4.2 (0.1–21.1) | 0, 0.0 (0.0–33.6) | 1, 3.0 (0.1–15.8) |
Any type not classified as oncogenic by IARCd | 18, 2.6 (1.5–4.0) | 0, 0.0 (0.0–10.6) | 0, 0.0 (0.0–14.2) | 0, 0.0 (0.0–33.6) | 0, 0.0 (0.0–10.6) |
HPV negativee | 4, 0.6 (1.2–1.5) | 1, 3.0 (0.1–15.8) | 0, 0.0 (0.0–14.2) | 0, 0.0 (0.0–33.6) | 0, 0.0 (0.0–10.6) |